Early clinical case studies
Discover how our expertise and innovative solutions have successfully advanced clinical trials and drug development.
With extensive medical and operational experience, we deliver seamless execution in both healthy volunteer and patient cohort studies, providing critical safety and tolerability data in the early clinical stages of development.
Overcoming enrollment challenges in an early phase obesity trial
A leading multinational pharmaceutical company partnered with ICON to conduct a phase 1 obesity study assessing the safety and tolerability of a new investigational oral amycretin therapy.
Complex phase 1 obesity study
ICON was once again selected as a partner to conduct a phase 1 study in individuals who are overweight or have obesity, evaluating the safety and tolerability of a new subcutaneous GLP-1 and amylin peptide formulation.
Early phase study for non-opioid pain treatment
A leading biotech company developing a groundbreaking non-opioid treatment for moderate-to-severe acute pain partnered with ICON to conduct a series of early-phase trials.
Rapid IV formulation development for FIH ADME study
Analytical method development, validation, stability testing and compatibility assessments for a large pharma sponsor.
Multinational phase 1 biosimilar study
ICON conducted a multinational biosimilar phase 1 study for multiple sclerosis (MS). This trial was performed under high regulatory scrutiny and challenging pandemic conditions, with increased dosing targets requiring additional site activation.
Volunteer recruitment for an early phase hot flash study
ICON assisted in the recruitment of participants for a hot flash study that had a set of complex eligibility requirements.
Success in early phase psoriasis study
A randomised, double-blind, placebo-controlled study on behalf of a biotechnology organisation to evaluate the safety, tolerability, and efficacy of the study drug in subjects with moderate to severe plaque psoriasis.